Statement: most participants in the secondary trial and the primary trial did not suffer from Enterocolitis. microkatal is a unit of catalytic activity measurement equal to one millionth of katal (10e-6 katal).
Primary_evidence: Adverse Events 1:   Total: 20/167 (11.98%)   Cardiac failure acute 0/167 (0.00%)   Diarrhoea 5/167 (2.99%)   Colitis 2/167 (1.20%)   Enterocolitis 1/167 (0.60%)   Enterocolitis haemorrhagic 1/167 (0.60%)   Stomatitis 1/167 (0.60%)   Impaired healing 1/167 (0.60%)   Sudden death 1/167 (0.60%)   Postoperative wound infection 2/167 (1.20%)   Erysipelas 2/167 (1.20%)   Bacterial diarrhoea 1/167 (0.60%) Adverse Events 2:   Total: 4/167 (2.40%)   Cardiac failure acute 1/167 (0.60%)   Diarrhoea 0/167 (0.00%)   Colitis 0/167 (0.00%)   Enterocolitis 0/167 (0.00%)   Enterocolitis haemorrhagic 0/167 (0.00%)   Stomatitis 0/167 (0.00%)   Impaired healing 0/167 (0.00%)   Sudden death 0/167 (0.00%)   Postoperative wound infection 1/167 (0.60%)   Erysipelas 0/167 (0.00%)   Bacterial diarrhoea 0/167 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 112/458 (24.45%)   Febrile neutropenia 8/458 (1.75%)   Neutropenia 6/458 (1.31%)   Anaemia 3/458 (0.66%)   Thrombocytopenia 3/458 (0.66%)   Pancytopenia 2/458 (0.44%)   Myocardial infarction 0/458 (0.00%)   Pericardial effusion 0/458 (0.00%)   Tachycardia 0/458 (0.00%)   Acute myocardial infarction 1/458 (0.22%)   Atrial fibrillation 0/458 (0.00%) Adverse Events 2:   Total: 39/221 (17.65%)   Febrile neutropenia 5/221 (2.26%)   Neutropenia 1/221 (0.45%)   Anaemia 2/221 (0.90%)   Thrombocytopenia 0/221 (0.00%)   Pancytopenia 0/221 (0.00%)   Myocardial infarction 2/221 (0.90%)   Pericardial effusion 2/221 (0.90%)   Tachycardia 2/221 (0.90%)   Acute myocardial infarction 0/221 (0.00%)   Atrial fibrillation 1/221 (0.45%)